⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
PCVX — Vaxcyte, Inc.
Last scan (Oct. 6, 2026): price $73.82, RSI 76.59, relative volume 9.96x, MACD ⚪ No, score 70.00.
It's in a bullish underlying trend, but an RSI of 76.59 already puts it in technically overbought territory — the next leg could come with more volatility. The price just broke its 20-day high, though the MACD doesn't confirm the move yet. Today's volume is 9.96x average — well above normal activity, a sign of real interest. The analysts' average target price implies +45.1% upside — one of the score's strongest signals. Today it holds rank #6 in the Medium group on Smart Scanner's upside + relative volume ranking.
Price chart
PCVX
Price: $73.96 · RSI (14): 65.01 · Rel. volume: 2.01x · Breakout: No
- Current price: ($73.96) — solid white line — the latest available closing price.
- Target price: ($107.12) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($55.08) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
PCVX
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal…
- Buy 9
- Hold 1
- Sell 0
Average target price: $107.12 (+45.1% vs. current price) · range $67.0 – $163.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
?
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Not enough data to calculate it (no recent earnings or data unavailable).
?
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
?
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Not enough data (requires future growth estimates).
?
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Low leverage: conservative balance sheet, less risk if interest rates rise.
?
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
?
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
?
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
More volatile than the market: higher potential gain, but also higher potential loss.
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.